https://www.marketscreener.com/quote/stock/ANAPTYSBIO-INC-33634949/news/Anaptys-to-Present-Phase-1-Data-on-ANB032-its-BTLA-Agonist-Antibody-at-the-32nd-EADV-Congress-45040493/?utm_source=telegram&utm_medium=social&utm_campaign=share